APJ agonist nanobody therapeutics - BioAge Labs
Latest Information Update: 23 Jun 2025
At a glance
- Originator ShanghaiTech University
- Developer BioAge Labs
- Class Obesity therapies; Single-domain antibodies
- Mechanism of Action Apelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity